Cytokinetics Inc (CYTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytokinetics Inc (CYTK) has a cash flow conversion efficiency ratio of 0.176x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-145.46 Million) by net assets ($-826.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CYTK days of operational coverage to measure how many days the company can operate on defensive assets alone.
Cytokinetics Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Cytokinetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cytokinetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytokinetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MP Materials Corp
NYSE:MP
|
-0.018x |
|
Hubei Feilihua Quartz Glass Co Ltd
SHE:300395
|
0.003x |
|
Antero Midstream Partners LP
NYSE:AM
|
0.123x |
|
TTM Technologies Inc
NASDAQ:TTMI
|
0.052x |
|
Leader Harmonious Drive Systems Co Ltd
SHG:688017
|
0.022x |
|
Vanguard International Semiconductor
TWO:5347
|
0.092x |
|
Prada S.p.A.
F:PRP
|
0.080x |
|
Deutsche Lufthansa AG
F:LHAB
|
0.008x |
Annual Cash Flow Conversion Efficiency for Cytokinetics Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Cytokinetics Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see CYTK market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-659.62 Million | $-510.01 Million | 0.773x | -73.56% |
| 2024-12-31 | $-135.37 Million | $-395.89 Million | 2.924x | +172.68% |
| 2023-12-31 | $-386.32 Million | $-414.33 Million | 1.073x | -61.36% |
| 2022-12-31 | $-107.90 Million | $-299.52 Million | 2.776x | +574.97% |
| 2021-12-31 | $243.86 Million | $-142.52 Million | -0.584x | -840.97% |
| 2020-12-31 | $113.38 Million | $8.94 Million | 0.079x | -99.05% |
| 2019-12-31 | $-10.94 Million | $-90.91 Million | 8.312x | +312.97% |
| 2018-12-31 | $25.93 Million | $-101.22 Million | -3.903x | -321.28% |
| 2017-12-31 | $109.84 Million | $-101.76 Million | -0.926x | -336.38% |
| 2016-12-31 | $94.36 Million | $36.98 Million | 0.392x | +450.52% |
| 2015-12-31 | $68.59 Million | $4.88 Million | 0.071x | +114.62% |
| 2014-12-31 | $92.06 Million | $-44.84 Million | -0.487x | -243.58% |
| 2013-12-31 | $54.44 Million | $-7.72 Million | -0.142x | +69.71% |
| 2012-12-31 | $71.44 Million | $-33.44 Million | -0.468x | +50.54% |
| 2011-12-31 | $48.18 Million | $-45.59 Million | -0.946x | -48.86% |
| 2010-12-31 | $70.52 Million | $-44.83 Million | -0.636x | -866.19% |
| 2009-12-31 | $101.43 Million | $8.42 Million | 0.083x | +106.73% |
| 2008-12-31 | $49.77 Million | $-61.33 Million | -1.232x | -3997.48% |
| 2007-12-31 | $99.92 Million | $-3.00 Million | -0.030x | +93.22% |
| 2006-12-31 | $106.31 Million | $-47.17 Million | -0.444x | +17.34% |
| 2005-12-31 | $73.56 Million | $-39.48 Million | -0.537x | -69.64% |
| 2004-12-31 | $107.56 Million | $-34.03 Million | -0.316x | -195.43% |
| 2003-12-31 | $-92.03 Million | $-30.51 Million | 0.332x | -9.93% |
| 2002-12-31 | $-60.59 Million | $-22.30 Million | 0.368x | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more